Outcomes of Acute Kidney Injury in Critically Ill Patients

Outcomes of Acute Kidney Injury in Critically Ill Patients in Luxor International Hospital

this study to evaluate the frequency of acute kidney injury in critically ill patients in intensive care units.

Study Overview

• Status: Unknown
• Conditions: Acute Kidney Injury
• Intervention / Treatment: Diagnostic test: renal function test

Detailed Description

Acute kidney injury (AKI) affects approximately 20% of hospitalized patients and up to 67% of those admitted to an intensive care unit (ICU), making it among the most common organ dysfunctions among the critically ill . Depending on severity, Acute kidney injury (AKI) contributes to short-perimortality rates between 40% and 70% , and survivors are at increased risk for chronic kidney disease (CKD) and late death.

The diagnosis of Acute kidney injury (AKI) is only considered after achieving an adequate status of hydration and after excluding urinary obstruction; Acute kidney injury (AKI) is defined by the sudden decrease (in 48 h) of renal function, defined by an increase in absolute serum creatinine of at least (0.3 mg/dL) or by a percentage increase in serum creatinine ≥50% (1.5× baseline value), or by a decrease in the urinary output (documented oliguria <0.5 mL/kg/h for more than 6hours).

The purpose of this study was to benchmark the outcomes of acute kidney injury in a critically ill surgical patients.We hypothesized that renal dysfunction in this population is common and is associated with a significantly higher burden of morbidity, mortality, and resource utilization

• Study Type: Observational
• Enrollment (Anticipated): 40

Contacts and Locations

• Study Contact: Name: Alaa H Fahmy; Phone Number: 00201118929161; Email: alaaheshmat90@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

patient willl be recruited from critical care units in Luxor international hospital

Description

Inclusion Criteria:

• All patient with acute kidney injury in critical care units in Luxor international hospital

Exclusion Criteria:

• Patients on chronic dialysis
• Previous acute kidney injury
• Nephrectomy
• Organ transplant
• Chronic kidney disease

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Participants; all patients recruited in the trial will be investigated for renal function test	Diagnostic test: renal function test; 2 ml blood sample to be investigated for renal function test

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acute kidney injury in critically ill patients	To evaluate the frequency of acute kidney injury in critically ill patients admitted in intensive care units.	10 days

Collaborators and Investigators

• Sponsor: Alaa H Fahmy
• Investigators: Study Director: Ahmed M Aly, professor, Professor of Internal Medicine

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2017
• Primary Completion (Anticipated): June 30, 2018
• Study Completion (Anticipated): June 30, 2018

Study Registration Dates

• First Submitted: November 1, 2017
• First Submitted That Met QC Criteria: November 7, 2017
• First Posted (Actual): November 9, 2017

Study Record Updates

• Last Update Posted (Actual): November 13, 2017
• Last Update Submitted That Met QC Criteria: November 8, 2017
• Last Verified: November 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency; Wounds and Injuries; Acute Kidney Injury
• Other Study ID Numbers: AssiutU AHFahmy

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No